Kornimate/medical-research-clean huggingface dataset:
collection of sequential samples from patients with malignant myeloid hemopathy for the study of treatment resistance

Conditions: Hematologic Cancer

Summary: the main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with it resistance through the constitution of a collection associating blood or marrow samples from patients with la, mds and mps marrow samples from patients with la, mds and mps at diagnosis, during treatment and at relapse and relapse and clinical annotations.

it is a collection of blood, marrow and oral epithelial cell samples taken longitudinally and oral epithelial cells taken longitudinally for each patient included, with each patient included, with the corresponding clinical data. an oral epithelial cell sample will be collected at inclusion from 2 swabs, which will allow extraction of dna from healthy from healthy cells. during blood sampling necessary for care, an additional 40 ml of blood will be collected of 40 ml of blood will be collected in 10 tubes of 4 ml: 4 edta tubes, 4 heparinized heparinized tubes and 2 dry tubes. these additional collections will take place at the following times: * at inclusion * 7 days (+/- 2 days) after initiation of treatment * 14 days (+/- 2 days) after initiation of therapy * 21-42 days after initiation of therapy (early response assessment) * in case of complete remission * in case of relapse or progression during bone marrow punctures required for treatment, 6 ml of bone marrow bone marrow will be collected in 2 tubes of 3 ml: 1 edta tube and 1 heparinized tube. heparinized tube. these additional collections will take place at the following times following times: * at inclusion * 21-42 days after initiation of treatment (assessment of early response) early response) * in case of complete remission * in case of relapse or progression patients will be followed for up to 2 years after inclusion.

Eligibility criteria:
inclusion criteria: 1. diagnosis of acute leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (cmml) or myeloproliferative syndrome according to the who classification 2016, 2. patient for whom a new line of therapy is initiated. 3. patient older than 18 years of age. 4. patient affiliated to the social security system or benefiting from such a system. 5. signed consent to participate. exclusion criteria: 1. weight at inclusion \< 50 kg 2. participating in another clinical study that would cause the total amount of blood collection to exceed the and endanger the patient 3. person in an emergency situation, adult under legal protection (guardianship, curatorship, etc.) protection (guardianship, curatorship or safeguard of justice), or unable to express his or her consent. 4. impossibility to submit to the medical follow-up of the trial for geographical social or psychological reasons, 5. pregnant or breastfeeding women
safety and efficacy of cariprazine for bipolar i disorder

Conditions: Mania; Bipolar I Disorder

Summary: the objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar i disorder.


Eligibility criteria:
inclusion criteria: * patients who have provided informed consent prior to any study specific procedures * patients currently meeting the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) criteria for bipolar i disorder, as confirmed by the structured clinical interview for diagnostic and statistical manual of mental disorders, fourth edition (scid) manic or mixed type with or without psychotic symptoms * voluntarily hospitalized for current manic episode * patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ecg) exclusion criteria: * patients with a dsm-iv-tr diagnosis of an axis i disorder other than bipolar i disorder that was the primary focus of treatment within the previous six months

Keywords: acute mania bipolar i disorder
computational prediction and experimental validation of esophageal cancer associated neoantigens

Conditions: Esophageal Cancer; Neoantigen

Summary: this study is to develop computational pipelines and experimental validation assays for improving the identification of neoantigens from patients with esophageal cancer.

esophageal cancer (ec) is the common malignant tumor with poor survival. the long-term surival rate of patients with advanced ec stages has not been improved with multidisciplinary treatments including surgery and chemotherapy and radiation. recently, immunotherapy approaches using checkpoint inhibitors (cpi), cancer vaccine, and adoptive t cell therapy have improved survival outcomes of ec patients. the clinical outcomes are associated with expression levels as well as the immunogenicity of neoantigens which arise from soma mutations. therefore, the identification of immunogenic neoantigens is essential for achieving effective therapies. recent data published by the tumor neoantigen selection alliance (tesla) show that the majority (98%) of predicted neoantigens are lack of immunogenicity and ineffective in activating antitumor immune responses. in our study, we aim to develop a pipeline with both computational prediction tools and experimental validation assays to enhance the accuracy of neoantigen identification.

Eligibility criteria:
inclusion criteria: 1. male or female patients aged 18 years and older 2. diagnosed with advanced esophageal cancer 3. treatment-naive 4. not known for other concomitant cancers 5. provide written informed consent exclusion criteria: 1. insufficient tumor tissues (less than 1 cm3 ) 2. unable to sign informed consent 3. underwent treatment
exercise for preventing the metabolic syndrome in latinoamerican amerindians

Conditions: Obesity; Cardiovascular Risk Factor; Physical Activity

Summary: despite exercise training decrease blood fasting glicaemy in 'average' terms, there is a wide inter-individual variability after exercise training explored mainly in adults but not in adults with prediabetes comorbidities. thus, is yet unknown the effects and influence of the concurrent training (ct) eliciting responders (r) and non-responders (nr) cases (i.e., percentage of subjects who experienced a non-change/worsened response after training in some metabolic outcomes).


Eligibility criteria:
inclusion criteria: * written informed consent * interested in improving health and fitness exclusion criteria: * cardiovascular contraindications to exercise * history of stroke, asthma or chronic obstructive pulmonary disease, muscle-skeletal disorders * smoking * a compliance rate to the exercise program ≥ 70% was required for the participants in the intervention group to be included in the statistical analyses.
intrafetal digoxin as an adjuvant for dilation and evacuation at 20 to 24 weeks' gestation

Conditions: Abortion

Summary: this is a research study to measure the effect of digoxin injection on dilation and evacuation (d\&e) procedure duration. digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient preference, and concerns over legal status of later d\&e procedures. there have been several studies on digoxin administration, adverse effects, and impact on the d\&e procedure, but doctors want to clarify how digoxin effects d\&e procedure time, if at all.


Eligibility criteria:
inclusion criteria: * 20 weeks 0 days-24 weeks 0 days gestation * english or spanish speaking * 18 years or older exclusion criteria: * under 18 * contraindications to digoxin
different levels of patient education for care of ostomy site

Conditions: Ostomy

Summary: this is a randomized study of standard versus extra ostomy education.

the purpose of this study is to evaluate the effectiveness of pre-operative and post-operative ostomy education compared to standard of care ostomy education.

Eligibility criteria:
inclusion criteria: * age equal to or greater than 18 years of age at the time of consent. * scheduled to undergo surgery at iu health north hospital that will results in a temporary or permanent colostomy or ileostomy for a benign or malignant disease process. * are willing and able to provide written informed consent for participation in the study and authorization for release of health information. * are willing and able to attend up to two additional clinic visits at iu health north hospital for the purpose of ostomy teaching and care. * subjects who currently do not have a urostomy or any other type of urinary diversion and/or are not planning to have a urostomy or any other type of urinary diversion as part of the surgery procedures at the time of their surgery for placement of colostomy or ileostomy. * subjects who do not have any history of prior colostomy or ileostomy. exclusion criteria: * subjects not meeting any of the above eligibility criteria.

Keywords: ostomy education education care of ostomy site
fred and fred jr devices for intracranial aneurysm treatment

Conditions: Intracranial Aneurysm

Summary: a french, multicenter, prospective, observational, "real-world" assessment of the safety and efficacy of fred and fred jr devices in the treatment of intracranial aneurysms

post market clinical follow-up. multicenter observational study. treatment and follow-up far at least 12 months as per standard of care. sample size: 138 patients.

Eligibility criteria:
inclusion criteria: * patient with an intracranial aneurysm for which an endovascular treatment is indicated with the device fred or fred jr * patient or patient's legally authorized representative has been informed about the study and does not oppose the collection of his/her personal data exclusion criteria: * none

Keywords: aneurysm endovascular flow-diverter
effect of sesame oil in preventing phlebitis

Conditions: Phlebitis After Infusion

Summary: background: to determine the effect of sesame oil in preventing phlebitis that may occur during intravenous therapy in patients undergoing cardiac surgery. material and method: a randomized controlled interventional study will be conducted with patients treated in the coronary intensive care unit of a university hospital. the population of the study will be the patients hospitalized in the intensive care unit after cardiac surgery and administered parenteral amiodarone infusion. the power analysis was carried out by taking the study by. the sample size was determined as 44 patients. personal information form and visual infusion phlebitis scale will be used to collect data. sesame oil will be applied to the patients in the intervention group as 10 drops, 10 cm around the cannula, for 10 minutes. this administration will be repeated every eight hours during the 24-hour amiodarone infusion. no application will be made by the researcher to the patients in the control group. at the end of each 24 hours, patients in both groups will be evaluated by the investigator on the visual infusion phlebitis scale. descriptive statistics, chi square, independent t test and fisher's exact test will be used to evaluate the data.

no application was made to the patients assigned to the control group. sesame oil was applied by the researcher to the patients assigned to the intervention group. sesame oil was applied to the 10 cm circumference of the cannula by applying 10 drops and 10 minutes. this application was repeated every eight hours during the 24-hour amiodarone infusion. the area where the intravenous line is located is covered with a standard transparent dressing (tegaderm) so that it can be observed. patients in the intervention and control groups were evaluated for phlebitis at the end of every 24 hours (1st day, 2nd day, 3rd day) according to the vip scale. the highest of the phlebitis stages obtained as a result of the evaluation was accepted as the final evaluation.

Eligibility criteria:
inclusion criteria: * patients who had undergone cardiac surgery, * were over 18 years old, * were conscious, could communicate, * were not allergic to sesame, * were administered prophylactic rhythm regulator * amiodarone as a treatment were included in the study. exclusion criteria: * who was with cancer, * who was with diabetes mellitus, * who was with hypertension * who was with peripheral vascular disease * patients who had myocardial infarction during the procedure, * received immunosuppressive therapy, * underwent resuscitation and could not use an intravenous catheter for any reason

Keywords: aromatherapy amiodarone infusion phlebitis cardiac surgery sesame oil
retrospective analysis of long-term speech performance in cochlear implant recipients using electro-acoustic stimulation

Conditions: Cochlear Hearing Loss

Summary: this is a retrospective study designed to collect long-term speech perception results for cochlear implants recipients using electro-acoustic-stimulation as measured in the clinical routine and to confirm the performance of sound processors associated with acoustic earhooks.


Eligibility criteria:
inclusion criteria: * being implanted with hires ultra or hires ultra 3d slimj * being a user of the "acoustic earhook" system * having provided informed consent regarding use of his/her data for research. exclusion criteria: * no exclusion criteria
effects of mcdg oil on postprandial lipid metabolism

Conditions: Hyperlipidemias; Triglycerides High

Summary: it is well known that medium chain triglycerides (mcts) and diacylglycerols (dgs) have effects on lowering circulating triglycerides (tgs). in this study, the mixture of mcts and dgs (mcdgs) examined whether it has beneficial effects on postprandial lipids metabolism compared to long-chain triglycerides (tgs).

a randomized, double-blinded, controlled, cross-over trial was conducted to verify the effects of mcdgs. twenty-eight healthy male and female subjects aged 21-29 years with normal body weight \[18.5 kg/m\^2 ≤ body mass index (bmi) \< 25 kg/m\^2\] were recruited. the subjects visited the research site twice over with a seven-day interval after an overnight fast at least 12 hr. on the first visit, the participants were randomly assigned to consume a test or placebo product \[test product: muffins containing mcdg oil (mcdg muffin); placebo product: muffins containing lct oil (lct muffin)\] and ingested the assigned product. on the second visit, the participants consumed the other product that they did not eat on the first visit. on both visit day, the 6-hr meal tolerance test was conducted and started at 8:00 in the morning; venous blood samples were collected before (0 hr) and after ingestion (2, 3, 4, and 6 hr) of the products.

Eligibility criteria:
inclusion criteria: * healthy subjects with normal body weight (18.5 kg/m\^2 ≤ body mass index (bmi) \< 25 kg/m\^2) exclusion criteria: * history/presence of hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, liver disease, gastrointestinal disease, thyroid disease, or any other acute or chronic diseases requiring treatment * use of any medication affecting body weight or energy expenditure for 1 month before screening

Keywords: postprandial lipid metabolism medium-chain triglycerides diacylglycerols serum triglycerides chylomicron triglycerides
neurobiological and psychological maintenance mechanisms associated with anticipatory reward in bulimia nervosa

Conditions: Bulimia Nervosa

Summary: the purpose of this investigation is to identify the potentially crucial role of anticipatory reward mechanisms maintaining bulimic behavior (i.e., binge eating and purging) in bulimia nervosa (bn). the research will investigate neural and psychological anticipatory processes in bn, both in the scanner and the natural environment.

bulimia nervosa (bn), an eating disorder characterized by recurrent bulimic episodes of binge eating and often persists in spite of treatment, likely indicating ineffectively targeted maintenance mechanisms. treatment outcome data suggest that \ 75%) of individuals with bn report "planning" some or most of their bulimic episodes. thus, determining the role of reward anticipation in bn will facilitate the application of novel interventions that more precisely target these neglected mechanisms. further, research indicates that reward mechanisms become increasingly focused on anticipation in later phases of reward learning. therefore, it is important to determine how reward anticipation processes contribute to the maintenance of bulimic behaviors and interact with illness duration to facilitate bn chronicity. the purpose of this investigation is to identify the potentially crucial role of anticipatory reward mechanisms maintaining bulimic behavior (i.e., binge eating and purging) in bulimia nervosa (bn). the research will investigate neural and psychological anticipatory processes in bn, both in the scanner and the natural environment.

Eligibility criteria:
inclusion criteria: bulimia nervosa (bn) and healthy control (hc) groups: * right-handed * ability to read and speak in english bn group only: * eating disorder examination (ede) diagnosis of bn (i.e., at least one objective bulimic episode and one self-induced vomiting episode per week for at three months) with binge episodes always accompanied by self-induced vomiting * stable dose for at least 6 weeks of any recent changes in medication impacting mood, appetite, or weight hc group only: * no binge eating or purging episodes for the past three months on the ede * no current or past history of an eating disorder as diagnosed by structured clinical interview for dsm-5 disorders exclusion criteria: * history of gastric bypass surgery * medical condition acutely affecting eating behavior and/or weight (i.e., pregnancy, lactation, thyroid disease) * current medical or psychiatric instability (i.e., hospitalization required in the past three months) * lifetime history of psychosis or bipolar disorder * history of neurological disorder or injury (i.e., stoke, head injury with \>10 minutes loss of consciousness) * current substance use disorder * bmi less than 19 kg/m\^2 * acute suicidality requiring hospitalization * fmri exclusions as specifiedd by the center for magnetic resonance research * food allergy that cannot be accommodated through substitutions to the laboratory test snack
comparison of dr-2011 to a progesterone vaginal gel for luteal phase replacement

Conditions: Infertility

Summary: this is a single-center, open-label, randomized, active-controlled study to compare dr-2011 to progesterone vaginal gel for luteal phase replacement.

this is a 2-arm, single-center, open-label, randomized, active-controlled study to compare the safety and efficacy of luteal phase replacement with dr-2011 to progesterone vaginal gel over an 18-day treatment period. patients will also be required to use an estrogen patch during the course of the study. the overall study duration for each patient will be approximately 1½ months. luteal phase replacement will be monitored by endometrial biopsy on cycle day 25 or 26. in addition, serum hormonal levels will be measured at screening and at designated times from cycle day 14 to 31.

Eligibility criteria:
inclusion criteria: * not pregnant * clinically or medically-induced non-functioning or surgically removed ovaries * clinical investigator believes patient would be eligible for oocyte donation exclusion criteria: * any contraindication to progesterone or estrogen therapy * undiagnosed vaginal bleeding * history of uterine fibroids or any other conditions that could adversely affect pregnancy success * hysterectomy * any contraindication to vaginal drug delivery systems

Keywords: luteal phase replacement oocyte donation infertility progesterone
the comparison of single incision laparoscopic appendectomy and three port laparoscopic appendectomy

Conditions: Acute Appendicitis

Summary: laparoscopic techniques have allowed surgeons to perform complicated intrabdominal surgery with minimal trauma. in numerous studies, when conventional laparoscopic appendectomy using 3 ports is compared with open appendectomy, it has advantages of reduced pain, reduced hospital stay, and enhanced cosmetic effects. single incision laparoscopic surgery (sils) was developed with the aim of reducing the invasiveness of conventional laparoscopy. in this study the investigators aimed to compare results of sils appendectomy and three port conventional laparoscopic appendectomy prospectively.

total of 50 patients who undergoing laparoscopic appendectomy for acute appendicitis will randomly assign to undergo sils appendectomy group (n = 25) or three port laparoscopic appendectomy group (n= 25) according to a computer-generated table of random numbers. demographics (ie, age, gender, body mass index (bmi), american society of anesthesiology (asa) score, need for conversion to a standard or three port laparoscopic appendectomy, need for conversion to an open appendectomy will be recorded. outcome measures include operative morbidity, operative time, pain score, hospital stay. morbidity will be evaluated by rates of colonic leak, wound infection, intrabdominal abscess hospital readmission, and hernia.

Eligibility criteria:
inclusion criteria: * required laparoscopic cholecystectomy for gallbladder disease. exclusion criteria: * american society of anesthesiologists score (asa) more than iii, * patients had prior abdominal surgery, * pregnancy, * ongoing peritoneal dialysis, * lack of written informed consent.

Keywords: appendicitis, laparoscopy, single incision
an open-label, multicenter clinical trial with nivolumab (bms-936558) monotherapy in subjects with advanced or metastatic squamous cell (sq) non-small cell lung cancer (nsclc) who have received at least one prior systemic regimen for the treatment of stage iiib/iv sqnsclc

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of the study is to determine the occurrence of high-grade (ctcae v4.0 grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic squamous cell non-small cell lung cancer (sqnsclc) with progression of disease during or after at least 1 systemic therapy.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * ecog status: ps 0-1 \& ps 2 * subjects with histologically or cytologically-documented sqnsclc * subjects must have experienced disease progression or recurrence during or after one prior platinum doublet-based chemotherapy regimen * subjects must have evaluable disease by ct or mri per recist 1.1 criteria * subjects with treated or asymptomatic cns metastases * prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration * prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy, immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or standard or investigational agents for treatment of nsclc, must be completed 28 days prior to the first dose of nivolumab * males and females, ages 18 or older exclusion criteria: * subjects with untreated, symptomatic cns metastases * subjects with carcinomatous meningitis * subjects with active, known or suspected autoimmune disease. * subjects who received prior therapy with anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody (including ipilimumab or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized bms clinical trial for nivolumab or ipilimumab.